NVST Stock Recent News

Envista (NVST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BREA, Calif. , Jan. 27, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025.

I upgrade Envista stock to a buy due to its potential for increased profitability in 2025. The Implants segment, NVST's largest business unit, is expected to witness positive sales expansion in the coming quarters by capitalizing on its brand strength in a market with favorable recovery prospects. The clear aligner business targets to achieve positive operating profit for the current year, considering the appointment of new leadership and the company management's recent comments.

NVST's strong focus on international market expansion appears promising. Yet, a leveraged balance sheet is worrisome.

BREA, Calif. , Jan. 14, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its fourth quarter 2024 on Wednesday, February 5, 2025.

BREA, Calif. , Jan. 7, 2025 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in a presentation at the 43rd Annual J.P.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BREA, Calif. , Oct. 7, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") will report financial results for its third quarter 2024 on Wednesday, October 30, 2024.

BREA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that the company will participate in the Baird 2024 Global Healthcare Conference on Wednesday, September 11, 2024 from 10:50 – 11:20 am ET at the InterContinental New York Barclay.

Envista Holdings Corporation published Q2 2024 earnings results, highlighting a $1.2 billion non-cash charge from impairments. I find their valuation metrics quite attractive, comparing favorably to both the healthcare sector and their 5-year historical averages. Despite recent challenges, the company continues to generate positive free cash flows.